pdk4 expression Search Results


ihc staining for pdk4 expression  (Biomax Inc)
90
Biomax Inc ihc staining for pdk4 expression
Ihc Staining For Pdk4 Expression, supplied by Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ihc staining for pdk4 expression/product/Biomax Inc
Average 90 stars, based on 1 article reviews
ihc staining for pdk4 expression - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human pdk4 coding sequence  (Vigene Biosciences)
90
Vigene Biosciences human pdk4 coding sequence
High pyruvate dehydrogenase kinase 4 <t>(PDK4)</t> is associated with R‐CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) resistance in diffuse large B‐cell lymphoma (DLBCL) cells. A, Gene expression detected by RNA sequencing and expression of PDK4 in DLBCL patients. Hierarchical cluster analysis of the top 11 deregulated genes in R‐CHOP‐sensitive patients (n = 4) and R‐CHOP‐resistant patients (n = 3). Upregulated genes are shown in red and downregulated genes are shown in blue. B, PDK4 mRNA expression between germinal‐center B‐cell‐like (GCB)‐DLBCL (n = 30) and activated B‐cell‐like (ABC)‐DLCBL (n = 26) subtypes among 56 cases in the DLBCL cohort. * P < .05. C, D, Real‐time quantitative PCR analysis of PDK4 mRNA and MS4A1 mRNA expression in R‐CHOP‐sensitive patients (n = 37) and R‐CHOP‐resistant patients (n = 19) with DLBCL. E, Pearson correlation analysis for PDK4 and MS4A1 expression in 56 cases in the DLBCL cohort (Pearson r = −0.41, P = .0021, with F test). F, G, Assessment of mRNA and protein levels of PDK4 in R‐CHOP‐resistant DLBCL cell line SU‐DHL‐2/R and rituximab‐resistant DLBCL cell line OCI‐ly8/R, as well as their parental cell lines. H, Representative images of immunofluorescence analysis for PDK4 (red) and CD20 (green) protein expression in SU‐DHL‐2/R and parental cells. Scale bar, 15 μm
Human Pdk4 Coding Sequence, supplied by Vigene Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human pdk4 coding sequence/product/Vigene Biosciences
Average 90 stars, based on 1 article reviews
human pdk4 coding sequence - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


High pyruvate dehydrogenase kinase 4 (PDK4) is associated with R‐CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) resistance in diffuse large B‐cell lymphoma (DLBCL) cells. A, Gene expression detected by RNA sequencing and expression of PDK4 in DLBCL patients. Hierarchical cluster analysis of the top 11 deregulated genes in R‐CHOP‐sensitive patients (n = 4) and R‐CHOP‐resistant patients (n = 3). Upregulated genes are shown in red and downregulated genes are shown in blue. B, PDK4 mRNA expression between germinal‐center B‐cell‐like (GCB)‐DLBCL (n = 30) and activated B‐cell‐like (ABC)‐DLCBL (n = 26) subtypes among 56 cases in the DLBCL cohort. * P < .05. C, D, Real‐time quantitative PCR analysis of PDK4 mRNA and MS4A1 mRNA expression in R‐CHOP‐sensitive patients (n = 37) and R‐CHOP‐resistant patients (n = 19) with DLBCL. E, Pearson correlation analysis for PDK4 and MS4A1 expression in 56 cases in the DLBCL cohort (Pearson r = −0.41, P = .0021, with F test). F, G, Assessment of mRNA and protein levels of PDK4 in R‐CHOP‐resistant DLBCL cell line SU‐DHL‐2/R and rituximab‐resistant DLBCL cell line OCI‐ly8/R, as well as their parental cell lines. H, Representative images of immunofluorescence analysis for PDK4 (red) and CD20 (green) protein expression in SU‐DHL‐2/R and parental cells. Scale bar, 15 μm

Journal: Cancer Science

Article Title: Pyruvate dehydrogenase kinase 4‐mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B‐cell lymphoma by affecting the expression of MS4A1/CD20

doi: 10.1111/cas.15055

Figure Lengend Snippet: High pyruvate dehydrogenase kinase 4 (PDK4) is associated with R‐CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) resistance in diffuse large B‐cell lymphoma (DLBCL) cells. A, Gene expression detected by RNA sequencing and expression of PDK4 in DLBCL patients. Hierarchical cluster analysis of the top 11 deregulated genes in R‐CHOP‐sensitive patients (n = 4) and R‐CHOP‐resistant patients (n = 3). Upregulated genes are shown in red and downregulated genes are shown in blue. B, PDK4 mRNA expression between germinal‐center B‐cell‐like (GCB)‐DLBCL (n = 30) and activated B‐cell‐like (ABC)‐DLCBL (n = 26) subtypes among 56 cases in the DLBCL cohort. * P < .05. C, D, Real‐time quantitative PCR analysis of PDK4 mRNA and MS4A1 mRNA expression in R‐CHOP‐sensitive patients (n = 37) and R‐CHOP‐resistant patients (n = 19) with DLBCL. E, Pearson correlation analysis for PDK4 and MS4A1 expression in 56 cases in the DLBCL cohort (Pearson r = −0.41, P = .0021, with F test). F, G, Assessment of mRNA and protein levels of PDK4 in R‐CHOP‐resistant DLBCL cell line SU‐DHL‐2/R and rituximab‐resistant DLBCL cell line OCI‐ly8/R, as well as their parental cell lines. H, Representative images of immunofluorescence analysis for PDK4 (red) and CD20 (green) protein expression in SU‐DHL‐2/R and parental cells. Scale bar, 15 μm

Article Snippet: Human PDK4 coding sequence (Vigene Bioscience) was cloned into the pcDNA3.1 plasmid to generate a pcDNA/PDK4 expression plasmid.

Techniques: Gene Expression, RNA Sequencing, Expressing, Real-time Polymerase Chain Reaction, Immunofluorescence

High pyruvate dehydrogenase kinase 4 (PDK4) is associated with rituximab (RTX) resistance and low MS4A1/CD20 in diffuse large B‐cell lymphoma (DLBCL) cells. A, B, Real‐time quantitative PCR analysis of PDK4 and MS4A1 mRNA expression in DLBCL cell lines U2932, OCI‐ly7, and OCI‐ly8. C, Western blot analysis of PDK4 and CD20 protein levels in DLBCL cell lines U2932, OCI‐ly7, and OCI‐ly8. D, E, Annexin V‐phycoerythrin (PE)/7‐AAD double staining analysis of the three DLBCL cell lines treated with RTX (50 μg/mL). F, G, Mitochondrial membrane potential of DLBCL cells following treatment with RTX for 48 hours and stained with JC‐1 probe. Representative pictures of JC‐1 staining are shown. Scale bar, 25 μm. *** P < .001

Journal: Cancer Science

Article Title: Pyruvate dehydrogenase kinase 4‐mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B‐cell lymphoma by affecting the expression of MS4A1/CD20

doi: 10.1111/cas.15055

Figure Lengend Snippet: High pyruvate dehydrogenase kinase 4 (PDK4) is associated with rituximab (RTX) resistance and low MS4A1/CD20 in diffuse large B‐cell lymphoma (DLBCL) cells. A, B, Real‐time quantitative PCR analysis of PDK4 and MS4A1 mRNA expression in DLBCL cell lines U2932, OCI‐ly7, and OCI‐ly8. C, Western blot analysis of PDK4 and CD20 protein levels in DLBCL cell lines U2932, OCI‐ly7, and OCI‐ly8. D, E, Annexin V‐phycoerythrin (PE)/7‐AAD double staining analysis of the three DLBCL cell lines treated with RTX (50 μg/mL). F, G, Mitochondrial membrane potential of DLBCL cells following treatment with RTX for 48 hours and stained with JC‐1 probe. Representative pictures of JC‐1 staining are shown. Scale bar, 25 μm. *** P < .001

Article Snippet: Human PDK4 coding sequence (Vigene Bioscience) was cloned into the pcDNA3.1 plasmid to generate a pcDNA/PDK4 expression plasmid.

Techniques: Real-time Polymerase Chain Reaction, Expressing, Western Blot, Double Staining, Membrane, Staining

Inhibition of pyruvate dehydrogenase kinase 4 (PDK4) by shRNA or dichloroacetate (DCA) sensitizes diffuse large B‐cell lymphoma (DLBCL) cells to rituximab (RTX). A, B, Annexin V‐phycoerythrin (PE)/7‐AAD double staining analysis of DLBCL cells treated with RTX (50 μg/mL). Interference with PDK4 shRNA increased RTX‐induced cell apoptosis and caspase‐3 activation in U2932 and OCI‐Ly8 cell lines. C, PDK4 inhibitor dichloroacetate (DCA) enhanced the RTX‐induced apoptosis in DLBCL cell lines U2932, OCI‐ly7, and OCI‐Ly8. cop‐GFP, copepod super green fluorescent protein. * P < .05, ** P < .01

Journal: Cancer Science

Article Title: Pyruvate dehydrogenase kinase 4‐mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B‐cell lymphoma by affecting the expression of MS4A1/CD20

doi: 10.1111/cas.15055

Figure Lengend Snippet: Inhibition of pyruvate dehydrogenase kinase 4 (PDK4) by shRNA or dichloroacetate (DCA) sensitizes diffuse large B‐cell lymphoma (DLBCL) cells to rituximab (RTX). A, B, Annexin V‐phycoerythrin (PE)/7‐AAD double staining analysis of DLBCL cells treated with RTX (50 μg/mL). Interference with PDK4 shRNA increased RTX‐induced cell apoptosis and caspase‐3 activation in U2932 and OCI‐Ly8 cell lines. C, PDK4 inhibitor dichloroacetate (DCA) enhanced the RTX‐induced apoptosis in DLBCL cell lines U2932, OCI‐ly7, and OCI‐Ly8. cop‐GFP, copepod super green fluorescent protein. * P < .05, ** P < .01

Article Snippet: Human PDK4 coding sequence (Vigene Bioscience) was cloned into the pcDNA3.1 plasmid to generate a pcDNA/PDK4 expression plasmid.

Techniques: Inhibition, shRNA, Double Staining, Activation Assay

Pyruvate dehydrogenase kinase 4 (PDK4) has a negative regulatory effect on MS4A1/CD20 expression in diffuse large B‐cell lymphoma cells. A, B, Real‐time quantitative PCR analysis of PDK4 and MS4A1 mRNA expression in U2932 and OCI‐Ly8 cells transfected with PDK4 overexpressing (PDK4 OE) plasmid or empty vector (EV). C, D, CD20 (green) molecules in the plasma membrane showed a reduction after PDK4 overexpression in both U2932 and OCI‐Ly8 cells. Scale bar, 15 μm. E, F, Western blot analysis of PDK4 and CD20 protein levels in U2932 and OCI‐Ly8 cells with PDK4 shRNA interference or transfected with PDK4 OE plasmid or EV. * P < .05, ** P < .01, *** P < .001

Journal: Cancer Science

Article Title: Pyruvate dehydrogenase kinase 4‐mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B‐cell lymphoma by affecting the expression of MS4A1/CD20

doi: 10.1111/cas.15055

Figure Lengend Snippet: Pyruvate dehydrogenase kinase 4 (PDK4) has a negative regulatory effect on MS4A1/CD20 expression in diffuse large B‐cell lymphoma cells. A, B, Real‐time quantitative PCR analysis of PDK4 and MS4A1 mRNA expression in U2932 and OCI‐Ly8 cells transfected with PDK4 overexpressing (PDK4 OE) plasmid or empty vector (EV). C, D, CD20 (green) molecules in the plasma membrane showed a reduction after PDK4 overexpression in both U2932 and OCI‐Ly8 cells. Scale bar, 15 μm. E, F, Western blot analysis of PDK4 and CD20 protein levels in U2932 and OCI‐Ly8 cells with PDK4 shRNA interference or transfected with PDK4 OE plasmid or EV. * P < .05, ** P < .01, *** P < .001

Article Snippet: Human PDK4 coding sequence (Vigene Bioscience) was cloned into the pcDNA3.1 plasmid to generate a pcDNA/PDK4 expression plasmid.

Techniques: Expressing, Real-time Polymerase Chain Reaction, Transfection, Plasmid Preparation, Clinical Proteomics, Membrane, Over Expression, Western Blot, shRNA

Pyruvate dehydrogenase kinase 4 (PDK4) mediates the metabolic shift of rituximab‐resistant diffuse large B‐cell lymphoma cells. A‐D, U2932 and OCI‐ly8 cells were transfected with cop‐GFP or interfered PDK4 shRNA (PDK4‐sh1) and the glucose consumption (A), lactate production (B), ATP levels (C), and cellular extracellular acidification rate (ECAR) (D) were measured. E, OCI‐Ly8 cells were transfected with PDK4 overexpressing (PDK4 OE) plasmid or empty vector (EV). After treatment with or without dichloroacetate (DCA, 5 mM), cellular ECAR were measured. cop‐GFP, copepod super green fluorescent protein. * P < .05, ** P < .01

Journal: Cancer Science

Article Title: Pyruvate dehydrogenase kinase 4‐mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B‐cell lymphoma by affecting the expression of MS4A1/CD20

doi: 10.1111/cas.15055

Figure Lengend Snippet: Pyruvate dehydrogenase kinase 4 (PDK4) mediates the metabolic shift of rituximab‐resistant diffuse large B‐cell lymphoma cells. A‐D, U2932 and OCI‐ly8 cells were transfected with cop‐GFP or interfered PDK4 shRNA (PDK4‐sh1) and the glucose consumption (A), lactate production (B), ATP levels (C), and cellular extracellular acidification rate (ECAR) (D) were measured. E, OCI‐Ly8 cells were transfected with PDK4 overexpressing (PDK4 OE) plasmid or empty vector (EV). After treatment with or without dichloroacetate (DCA, 5 mM), cellular ECAR were measured. cop‐GFP, copepod super green fluorescent protein. * P < .05, ** P < .01

Article Snippet: Human PDK4 coding sequence (Vigene Bioscience) was cloned into the pcDNA3.1 plasmid to generate a pcDNA/PDK4 expression plasmid.

Techniques: Transfection, shRNA, Plasmid Preparation

Overexpression of pyruvate dehydrogenase kinase 4 (PDK4) promotes proliferation and rituximab resistance in diffuse large B‐cell lymphoma cells. A, In vitro cell growth assay showing relative cell growth curves of OCI‐Ly8 empty vector (EV) and OCI‐Ly8 PDK4 overexpressing (OE) cells treated with rituximab (RTX, 50 μg/mL) for indicated times. B, OCI‐Ly8 EV and PDK4 OE cells were treated with RTX for 48 hours, and cell viability rates were analyzed using CCK‐8 assays. C, D, F, in vivo xenograft mouse models of OCI‐ly8 PDK4 OE or OCI‐ly8 EV cells treated with RTX (12.5 mg/kg) or PBS. Differences in tumor weight (D) and tumor volume (F) are shown between those four groups (n = 4). E, Body weight of mice in each experimental group measured at day 24. NS P > .05 , * P < .05, ** P < .01

Journal: Cancer Science

Article Title: Pyruvate dehydrogenase kinase 4‐mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B‐cell lymphoma by affecting the expression of MS4A1/CD20

doi: 10.1111/cas.15055

Figure Lengend Snippet: Overexpression of pyruvate dehydrogenase kinase 4 (PDK4) promotes proliferation and rituximab resistance in diffuse large B‐cell lymphoma cells. A, In vitro cell growth assay showing relative cell growth curves of OCI‐Ly8 empty vector (EV) and OCI‐Ly8 PDK4 overexpressing (OE) cells treated with rituximab (RTX, 50 μg/mL) for indicated times. B, OCI‐Ly8 EV and PDK4 OE cells were treated with RTX for 48 hours, and cell viability rates were analyzed using CCK‐8 assays. C, D, F, in vivo xenograft mouse models of OCI‐ly8 PDK4 OE or OCI‐ly8 EV cells treated with RTX (12.5 mg/kg) or PBS. Differences in tumor weight (D) and tumor volume (F) are shown between those four groups (n = 4). E, Body weight of mice in each experimental group measured at day 24. NS P > .05 , * P < .05, ** P < .01

Article Snippet: Human PDK4 coding sequence (Vigene Bioscience) was cloned into the pcDNA3.1 plasmid to generate a pcDNA/PDK4 expression plasmid.

Techniques: Over Expression, In Vitro, Growth Assay, Plasmid Preparation, CCK-8 Assay, In Vivo

Model of our working hypothesis of rituximab resistance in diffuse large B‐cell lymphoma cells. OE, overexpressing; PDK4, pyruvate dehydrogenase kinase 4; R‐CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

Journal: Cancer Science

Article Title: Pyruvate dehydrogenase kinase 4‐mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B‐cell lymphoma by affecting the expression of MS4A1/CD20

doi: 10.1111/cas.15055

Figure Lengend Snippet: Model of our working hypothesis of rituximab resistance in diffuse large B‐cell lymphoma cells. OE, overexpressing; PDK4, pyruvate dehydrogenase kinase 4; R‐CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

Article Snippet: Human PDK4 coding sequence (Vigene Bioscience) was cloned into the pcDNA3.1 plasmid to generate a pcDNA/PDK4 expression plasmid.

Techniques: